After intravenous administration, the gold‐based nanoplatform successfully crossed the BBB, leading to a 26% reduction in Bcl2‐L12 gene expression and a 40% decrease in its protein levels in glioma cells.167. This evidence concerns the gene BCL2 and glioma.